A Phase 3 trial of the Bayer compound, regorafenib, in patients with metastatic gastrointestinal stromal tumours (GIST) has met its primary endpoint of progression-free survival, according to the sponsors. Data are being presented at Asco on 4 June. ---Subscribe to MedNous to access this article--- Company News Research & University News
